- Home
- AMGN vs TMO Comparison
AMGN vs TMO Comparison
Compare AMGN & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- TMO
- Stock Information
- Founded
- AMGN 1980
- TMO 1956
- Country
- AMGN United States
- TMO United States
- Employees
- AMGN N/A
- TMO N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- TMO Industrial Machinery/Components
- Sector
- AMGN Health Care
- TMO Industrials
- Exchange
- AMGN Nasdaq
- TMO Nasdaq
- Market Cap
- AMGN 157.5B
- TMO 159.1B
- IPO Year
- AMGN N/A
- TMO N/A
- Fundamental
- Price
- AMGN $292.51
- TMO $417.82
- Analyst Decision
- AMGN Hold
- TMO Buy
- Analyst Count
- AMGN 20
- TMO 17
- Target Price
- AMGN $322.30
- TMO $591.35
- AVG Volume (30 Days)
- AMGN 2.7M
- TMO 2.7M
- Earning Date
- AMGN 08-05-2025
- TMO 07-23-2025
- Dividend Yield
- AMGN 3.25%
- TMO 0.41%
- EPS Growth
- AMGN 56.16
- TMO 9.37
- EPS
- AMGN 10.94
- TMO 17.06
- Revenue
- AMGN $34,126,000,000.00
- TMO $42,898,000,000.00
- Revenue This Year
- AMGN $7.73
- TMO $2.96
- Revenue Next Year
- AMGN $1.78
- TMO $6.01
- P/E Ratio
- AMGN $26.78
- TMO $24.50
- Revenue Growth
- AMGN 15.56
- TMO 0.95
- 52 Week Low
- AMGN $253.30
- TMO $385.46
- 52 Week High
- AMGN $346.85
- TMO $627.88
- Technical
- Relative Strength Index (RSI)
- AMGN 52.53
- TMO 50.65
- Support Level
- AMGN $291.25
- TMO $411.88
- Resistance Level
- AMGN $302.38
- TMO $438.49
- Average True Range (ATR)
- AMGN 7.04
- TMO 12.79
- MACD
- AMGN 0.55
- TMO 1.22
- Stochastic Oscillator
- AMGN 66.26
- TMO 48.85
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).